Cancer Diagnosis – PLP Treatment Protocol
Possible Reactions - Post Therapy Maintenance
Cancer Diagnosis
Cancer diagnostics usually take place when disease starts manifesting itself through different symptoms which can’t be ignored by patient.
The whole routine consists of many tests available presently in hospitals including different types of tissue scans, visualization of hollow organs through endoscopy tools, blood tests for tumor markers; biopsy etc. but can detect only tumors when malignant tissue is already developed or in situ.
Risk of cancer or pre-cancerous conditions may be detected by means of mostly used presently blood test such as DR-70 which helps to recognize over 10 types of cancers at early or pre-stage conditions. The other one Alpha-fetoprotein AFA is the blood plasma glycoprotein which also may be used for a few types of pre-cancerous conditions, but its function in adult humans is still unknown.
As it was mentioned in “Brief Introduction of PLP treatment” pamphlet cancer is the Neurohumoral Systemic disease which manifests itself through uncontrollable cell division which leads to health decline and finally death.
It is recognized by conventional medicine as the terminal disease and all success rate statistics based on short terms of post therapy observations are incorrect.
The most scientific and logical way to approach cancer treatment is to find root problem or origin of disease which caused cell metabolism being affected, creating shortcuts of energy supply as the part of compensatory disease.
Our first goal is as the part of strategy, to find out “root problem” and the way how it started affecting the whole organism over a period of time.
The idea sounds like tracking back the process which took place long time ago should give clues and hints to approach each case individually, rather than using standard fixed protocols. Our standard routine work to identify and track root problem is as it follows:
* Quantum Plasma diagnostics where we use custom made analytical device which can gather information from organism in a form of frequencies, regarding health problems long time before they appeared at biochemical or morphological levels.
* 3D EEG (Electro Encephala Graph) is the new advanced version of regular EEG machine which allows us to see brain affected areas in colors, rather than in wave forms. Since cancer is Systemic Neurohumoral disease that is very useful to see which areas of limbic system are affected by stress, unresolved internal conflicts etc.
* Standard Hematology blood tests which are mostly used in hospitals to check different organs, system functions.
* ELISA (Enzyme-Linked Immunosorbent Assay) mostly designed to detect tumor markers, antigens, proteins etc., to see problem or metabolism abnormalities at microbiological level.
* EPI-Fluorescent, Dark field, Phase Contrast Microscopy are designed to study different blood cell structure, shape, size and their organelles. Blood samples are smeared across slide and stained with different dies, regarding investigation tasks.
Upon gathering all data we make assessment of therapy success and estimate further post treatment response.
However it is not advisable to go for regular cancer diagnostic tools, such as MRI, CT, PET etc. scans within next four, five weeks post PLP therapy.
The inflamed cancer tissue as the part of response of immune system may be misunderstood and taken wrong as cancer growth recurrence by conventional doctors who are not familiar with our research work and clinical trials. Also, we never recommend of going for biopsy (histology) tissue microscopy test. It has been proven scientifically many times, that even small puncture of tissue by needle causes cancer cell spread.
Since there is no comparison between PLP and conventional cancer therapies in terms of response, you can’t rely on test interpretations made by cancer doctor who has no practical experience and fully understands how it works and which internal mechanisms PLP has triggered.
That is good to know that responses at biochemical / microbiological levels completely different between conventional cancer therapies and PLP.
According to our experience to see how organism responded to PLP we do following analysis and ask our patients to go for them. Just a few major to mention.
NK (Natural Killer lymphatic cells) quantitative analysis
TNF (Tumor Necrosis Factor) formerly known as TNFα or TNF alpha, is the best-known member of this class. TNF is a monocyte-derived cytotoxin that has been implicated in tumor regression, septic shock, and cachexia.
Nineteen proteins have been identified as part of the TNF family on the basis of sequence, functional, and structural similarities.
TNF-related apoptosis inducing ligand (TRAIL), a cytokine that induces apoptosis.
T cell antigen gp39 (CD40L), a cytokine that seems to be important in B-cell development and activation.
CD27L, a cytokine that plays a role in T-cell activation. It induces the proliferation of co-stimulated T cells and enhances the generation of cytolytic T cells.
CD30L, a cytokine that induces proliferation of T cells.
FASL, a cell surface protein involved in cell death.
4-1BBL, an inducible T cell surface molecule that contributes to T-cell stimulation.
OX40L, a cell surface protein that co-stimulates T cell proliferation and cytokine production.
All members of the TNF family, with the exception of the secreted lymphotoxin and a proliferation-inducing ligand (APRIL), are type II transmembrane proteins that protrude from immune cells.
Such membrane-bound TNF ligands frequently signal back to the immune cells when they contact and bind their cognate receptors on other cells.
